抗体药物偶联物治疗晚期实体瘤的不良反应和处理措施

doi:10.3760/cma.j.cn371439-20220208-00039

摘要/Abstract

摘要：

新型抗体药物偶联物（ADC）是目前晚期实体瘤新药研发的热点,ADC药物在晚期乳腺癌、尿路上皮癌、胃癌等多种实体瘤治疗中具有显著疗效,但其眼毒性、肺毒性、血液学毒性、肝脏毒性等不良反应不可忽视,有效处理ADC药物的不良反应至关重要。

Abstract:

Novel antibody-drug conjugates （ADCs） are a hot spot in the research and development of new drugs for advanced solid tumors. ADCs have achieved significant efficacy in the treatment of advanced breast cancer, urothelial carcinoma, gastric cancer and other solid tumors, but their adverse reactions such as ocular toxicity, pulmonary toxicity, hematological toxicity, and liver toxicity cannot be ignored, and it is crucial to effectively deal with the adverse reactions of ADCs.

Key words: Antibody-drug conjugate, Adverse reactions, Occurrence mechanism, Treatment measures

庞静丹, 杜瀛瀛, 笪洁. 抗体药物偶联物治疗晚期实体瘤的不良反应和处理措施[J]. 国际肿瘤学杂志, 2022, 49(4): 220-224.

Pang Jingdan, Du Yingying, Da Jie. Adverse reactions and treatment measures of advanced solid tumors treated with antibody-drug conjugates[J]. Journal of International Oncology, 2022, 49(4): 220-224.

参考文献 45

[1]	Hafeez U, Parakh S, Gan HK, et al. Antibody-drug conjugates for cancer therapy[J]. Molecules, 2020, 25(20): 4764. DOI: 10.3390/molecules25204764. doi: 10.3390/molecules25204764
[2]	Makawita S, Meric-Bernstam F. Antibody-drug conjugates: patient and treatment selection[J]. Am Soc Clin Oncol Educ Book, 2020, 40: 1-10. DOI: 10.1200/EDBK_280775. doi: 10.1200/EDBK_280775 pmid: 32213087
[3]	王佳玉, 孙永琨, 朱铁楠, 等. 抗体药物偶联物治疗恶性肿瘤临床应用专家共识(2020版)[J]. 中国医学前沿杂志(电子版), 2021, 13(1): 1-15. DOI: 10.12037/YXQY.2021.01-01. doi: 10.12037/YXQY.2021.01-01
[4]	Eaton JS, Miller PE, Mannis MJ, et al. Ocular adverse events associated with antibody-drug conjugates in human clinical trials[J]. J Ocul Pharmacol Ther, 2015, 31(10): 589-604. DOI: 10.1089/jop.2015.0064. doi: 10.1089/jop.2015.0064
[5]	Patel SV, Dalvin LA. Corneal epitheliopathy associated with antibody-drug conjugates[J]. Mayo Clin Proc, 2021, 96(7): 2001-2002. DOI: 10.1016/j.mayocp.2021.03.021. doi: 10.1016/j.mayocp.2021.03.021
[6]	Banerji U, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study[J]. Lancet Oncol, 2019, 20(8): 1124-1135. DOI: 10.1016/S1470-2045(19)30328-6. doi: S1470-2045(19)30328-6 pmid: 31257177
[7]	Kreps EO, Derveaux T, Denys H. Corneal changes in trastuzumab emtansine treatment[J]. Clin Breast Cancer, 2018, 18(4): e427-e429. DOI: 10.1016/j.clbc.2018.03.005. doi: 10.1016/j.clbc.2018.03.005
[8]	Kim BY, Riaz KM, Bakhtiari P, et al. Medically reversible limbal stem cell disease: clinical features and management strategies[J]. Ophthalmology, 2014, 121(10): 2053-2058. DOI: 10.1016/j.ophtha.2014.04.025. doi: 10.1016/j.ophtha.2014.04.025
[9]	van den Bent M, Gan HK, Lassman AB, et al. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study[J]. Cancer Chemother Pharmacol, 2017, 80(6): 1209-1217. DOI: 10.1007/s00280-017-3451-1. doi: 10.1007/s00280-017-3451-1
[10]	Parrozzani R, Lombardi G, Midena E, et al. Corneal side effects induced by EGFR-inhibitor antibody-drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study[J]. Ther Adv Med Oncol, 2020, 12: 1758835920907543. DOI: 10.1177/1758835920907543. doi: 10.1177/1758835920907543
[11]	Narita Y, Muragaki Y, Kagawa N, et al. Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: a nonrandomized, phase 1/2 trial[J]. Cancer Sci, 2021, 112(12): 5020-5033. DOI: 10.1111/cas.15153. doi: 10.1111/cas.15153
[12]	Lee BA, Lee MS, Maltry AC, et al. Clinical and histological characterization of toxic keratopathy from depatuxizumab mafodotin (ABT-414), an antibody-drug conjugate[J]. Cornea, 2021, 40(9): 1197-1200. DOI: 10.1097/ICO.0000000000002595. doi: 10.1097/ICO.0000000000002595
[13]	Moore KN, Oza AM, Colombo N, et al. Phase Ⅲ, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD Ⅰ[J]. Ann Oncol, 2021, 32(6): 757-765. DOI: 10.1016/j.annonc.2021.02.017. doi: 10.1016/j.annonc.2021.02.017 pmid: 33667670
[14]	Matulonis UA, Birrer MJ, O’Malley DM, et al. Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetu-ximab soravtansine[J]. Clin Cancer Res, 2019, 25(6): 1727-1736. DOI: 10.1158/1078-0432.CCR-18-2474. doi: 10.1158/1078-0432.CCR-18-2474 pmid: 30413525
[15]	Manich CS, O’shaughnessy J, Aftimos PG, et al. LBA15 primary outcome of the phase Ⅲ SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer[J]. Ann Oncol, 2021, 32(Suppl-5): S1288. DOI: 10.1016/j.annonc.2021.08.2088. doi: 10.1016/j.annonc.2021.08.2088
[16]	Spira A, Lisberg A, Sands J, et al. OA03.03 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: updated results of TROPION-PanTumor01 phase 1 study[J]. J Thorac Oncol, 2021, 16(3): S106-S107. DOI: 10.1016/j.jtho.2021.01.280. doi: 10.1016/j.jtho.2021.01.280
[17]	Montemurro F, Ellis P, Anton A, et al. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1[J]. Eur J Cancer, 2019, 109: 92-102. DOI: 10.1016/j.ejca.2018.12.022. doi: S0959-8049(18)31577-6 pmid: 30708264
[18]	Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study[J]. Lancet Oncol, 2019, 20(6): 827-836. DOI: 10.1016/S1470-2045(19)30088-9. doi: S1470-2045(19)30088-9 pmid: 31047804
[19]	Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer[J]. N Engl J Med, 2020, 382(7): 610-621. DOI: 10.1056/NEJMoa1914510. doi: 10.1056/NEJMoa1914510
[20]	Kumagai K, Aida T, Tsuchiya Y, et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys[J]. Cancer Sci, 2020, 111(12): 4636-4645. DOI: 10.1111/cas.14686. doi: 10.1111/cas.14686
[21]	张剑, 沈维娜, 季冬梅, 等. 实体瘤中靶向药所致间质性肺病管理的复旦大学附属肿瘤医院标准[J]. 中国癌症杂志, 2021, 31(4): 241-249. DOI: 10.19401/j.cnki.1007-3639.2021.04.001. doi: 10.19401/j.cnki.1007-3639.2021.04.001
[22]	Thompson JA, Motzer RJ, Molina AM, et al. Phase Ⅰ trials of anti-ENPP3 antibody-drug conjugates in advanced refractory renal cell carcinomas[J]. Clin Cancer Res, 2018, 24(18): 4399-4406. DOI: 10.1158/1078-0432.CCR-18-0481. doi: 10.1158/1078-0432.CCR-18-0481 pmid: 29848572
[23]	Liu F, Ke J, Song Y. T-DM1-induced thrombocytopenia in breast cancer patients: new perspectives[J]. Biomed Pharmacother, 2020, 129: 110407. DOI: 10.1016/j.biopha.2020.110407. doi: 10.1016/j.biopha.2020.110407
[24]	Zhang J, Yang Y, Chen R, et al. Assessment of racial differences in the incidence of thrombocytopenia induced by trastuzumab emtansine: a systematic review and meta-analysis[J]. Ann Transl Med, 2021, 9(14): 1139. DOI: 10.21037/atm-21-2763. doi: 10.21037/atm-21-2763
[25]	Zhao H, Gulesserian S, Ganesan SK, et al. Inhibition of megakaryocyte differentiation by antibody-drug conjugates (ADCs) is mediated by macropinocytosis: implications for ADC-induced thrombocytopenia[J]. Mol Cancer Ther, 2017, 16(9): 1877-1886. DOI: 10.1158/1535-7163.MCT-16-0710. doi: 10.1158/1535-7163.MCT-16-0710 pmid: 28655784
[26]	Syed YY. Sacituzumab govitecan: first approval[J]. Drugs, 2020, 80(10): 1019-1025. DOI: 10.1007/s40265-020-01337-5. doi: 10.1007/s40265-020-01337-5
[27]	Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med, 2021, 384(16): 1529-1541. DOI: 10.1056/NEJMoa2028485. doi: 10.1056/NEJMoa2028485
[28]	Sheng X, Yan X, Wang L, et al. Open-label, multicenter, phase Ⅱ study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma[J]. Clin Cancer Res, 2021, 27(1): 43-51. DOI: 10.1158/1078-0432.CCR-20-2488. doi: 10.1158/1078-0432.CCR-20-2488
[29]	Spring LM, Nakajima E, Hutchinson J, et al. Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities[J]. Oncologist, 2021, 26(10): 827-834. DOI: 10.1002/onco.13878. doi: 10.1002/onco.13878
[30]	Hassan R, Blumenschein GR Jr, Moore KN, et al. First-in-human, multicenter, phase Ⅰ dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors[J]. J Clin Oncol, 2020, 38(16): 1824-1835. DOI: 10.1200/JCO.19.02085. doi: 10.1200/JCO.19.02085
[31]	Duret-Aupy N, Lagarce L, Blouet A, et al. Liver sinusoidal obstruction syndrome associated with trastuzumab emtansine treatment for breast cancer[J]. Therapie, 2019, 74(6): 675-677. DOI: 10.1016/j.therap.2019.03.010. doi: S0040-5957(19)30066-6 pmid: 31023619
[32]	Lepelley M, Allouchery M, Long J, et al. Nodular regenerative hyperplasia induced by trastuzumab emtansine: role of emtansine?[J]. Ann Hepatol, 2018, 17(6): 1067-1071. DOI: 10.5604/01.3001.0012.7207. doi: 10.5604/01.3001.0012.7207 pmid: 30600283
[33]	Yan H, Endo Y, Shen Y, et al. Ado-trastuzumab emtansine targets hepatocytes via human epidermal growth factor receptor 2 to induce hepatotoxicity[J]. Mol Cancer Ther, 2016, 15(3): 480-490. DOI: 10.1158/1535-7163.MCT-15-0580. doi: 10.1158/1535-7163.MCT-15-0580
[34]	中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 实用肝脏病杂志, 2017, 20(2): 后插1-后插18. DOI: 10.3969/j.issn.1672-5069.2017.02.039. doi: 10.3969/j.issn.1672-5069.2017.02.039
[35]	Yu EY, Petrylak DP, O’Donnell PH, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2021, 22(6): 872-882. DOI: 10.1016/S1470-2045(21)00094-2. doi: 10.1016/S1470-2045(21)00094-2
[36]	Viscuse PV, Marques-Piubelli ML, Heberton MM, et al. Case report: enfortumab vedotin for metastatic urothelial carcinoma: a case series on the clinical and histopathologic spectrum of adverse cutaneous reactions from fatal Stevens-Johnson syndrome/toxic epidermal necrolysis to dermal hypersensitivity reaction[J]. Front Oncol, 2021, 11: 621591. DOI: 10.3389/fonc.2021.621591. doi: 10.3389/fonc.2021.621591
[37]	Perez EA, Barrios C, Eiermann W, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase Ⅲ MARIANNE study[J]. J Clin Oncol, 2017, 35(2): 141-148. DOI: 10.1200/JCO.2016.67.4887. doi: 10.1200/JCO.2016.67.4887
[38]	Chang E, Weinstock C, Zhang L, et al. FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma[J]. Clin Cancer Res, 2021, 27(4): 922-927. DOI: 10.1158/1078-0432.CCR-20-2275. doi: 10.1158/1078-0432.CCR-20-2275
[39]	Noe MH, Micheletti RG. Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis[J]. Clin Dermatol, 2020, 38(6): 607-612. DOI: 10.1016/j.clindermatol.2020.06.016. doi: 10.1016/j.clindermatol.2020.06.016
[40]	Markham A. Tisotumab vedotin: first approval[J]. Drugs, 2021, 81(18): 2141-2147. DOI: 10.1007/s40265-021-01633-8. doi: 10.1007/s40265-021-01633-8
[41]	Mamounas EP, Untch M, Mano MS, et al. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE[J]. Ann Oncol, 2021, 32(8): 1005-1014. DOI: 10.1016/j.annonc.2021.04.011. doi: 10.1016/j.annonc.2021.04.011 pmid: 33932503
[42]	Rosenberg JE, O’Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2019, 37(29): 2592-2600. DOI: 10.1200/JCO.19.01140. doi: 10.1200/JCO.19.01140 pmid: 31356140
[43]	Coleman Rl, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study[J]. Lancet Oncol, 2021, 22(5): 609-619. DOI: 10.1016/S1470-2045(21)00056-5. doi: 10.1016/S1470-2045(21)00056-5 pmid: 33845034
[44]	马飞, 刘明生, 王佳妮, 等. 紫杉类药物相关周围神经病变规范化管理专家共识[J]. 中国医学前沿杂志(电子版), 2020, 12(03): 41-51. DOI: 10.12037/YXQY.2020.03-07. doi: 10.12037/YXQY.2020.03-07
[45]	Pace A, Brower B, Conway D, et al. Enfortumab vedotin: nursing perspectives on the management of adverse events in patients with locally advanced or metastatic urothelial carcinoma[J]. Clin J Oncol Nurs, 2021, 25(2): E1-E9. DOI: 10.1188/21.CJON.E1-E9. doi: 10.1188/21.CJON.E1-E9